251 286 - Biotech Bayern
251 286 - Biotech Bayern
251 286 - Biotech Bayern
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Contact:<br />
Dr. Günter Wich<br />
Zielstattstr. 20<br />
D-81379 München<br />
Phone: +49 (0) 89 74844-263<br />
Fax: +49 (0) 89 74844-350<br />
E-Mail: guenter.wich@wacker.com<br />
Internet: www.wacker.de<br />
Contact:<br />
Dr. Goetz Münch<br />
Am Klopferspitz 19<br />
D-82152 Martinsried<br />
Phone: +49 (0) 89 700 655 57<br />
Fax: +49 (0) 89 700 655 43<br />
E-Mail: muench@corimmun.com<br />
Internet: www.corimmun.com<br />
Contact:<br />
Christian Huber<br />
Schindmühlenerstr. 53<br />
D-93133 Burglengenfeld<br />
Phone: +49 (0) 9471 307 50<br />
Fax: +49 (0) 9471 307 501<br />
E-Mail: welcome@cowatec.com<br />
Internet: www.cowatec.com<br />
54<br />
Consortium für elektrochemische<br />
Industrie GmbH<br />
BIOTECH DEVICES & REAGENTS<br />
The Consortium für elektrochemische Industrie GmbH is the corporate research<br />
facility of Wacker Chemie GmbH. At the Consortium about 200 employees,<br />
which are organised in 30 research groups, are working in five areas of research:<br />
catalysis, polymers, function materials, organic synthesis and biotechnology.<br />
With core competences like biotransformation, metabolic engineering, protein<br />
production and fermentation, the research unit <strong>Biotech</strong>nology is mainly focused<br />
on production of biologicals and on the development of biological systems for<br />
synthesis of chiral organic compounds like cyclodextrins, amino acids and chiral<br />
alcohols.<br />
Corimmun GmbH<br />
BIOTECH THERAPEUTICS & DIAGNOSTICS<br />
Keywords: Drug Development, Peptide/Protein, Cardiovascular Diseases,<br />
Inflammation<br />
CORIMMUN is a spin-off from the universities of Würzburg and of Tübingen.<br />
The projects are funded by two grants of the GoBio project of the BMBF.<br />
Corimmun is funded by the Hightech Gründerfonds, <strong>Bayern</strong>kapital and Bio-M.<br />
The company will develop high-profile new drugs to treat congestive heart<br />
failure and atherosclerosis, the most common causes of mortality in developed<br />
countries. Two innovative products COR-1 and COR-2 are currently in preclinical<br />
development. COR-1 is a peptide drug candidate to prevent the auto-antibodymediated<br />
propagation of heart failure.<br />
COR-2 is a biological which prevents foam cell formation in atherosclerotic<br />
plaques. The founders and management of Corimmun bring together knowledge<br />
and reputation in research and clinical medicine together with biotech<br />
experience.<br />
Cowatec AG<br />
BIOTECH AGRO, FOOD, ENVIRONMENT<br />
Cowatec AG, based in Burglengenfeld in Bavaria, specialises in hi-tech biogas<br />
plants for the efficient generation of energy. Its range of services covers the<br />
planning, construction and operation of new plants, as well as the project optimisation<br />
of existing biogas projects.
Change language